Cartesian Therapeutics (RNAC) Other Operating Expenses (2023 - 2025)

Cartesian Therapeutics (RNAC) has 3 years of Other Operating Expenses data on file, last reported at $56.7 million in Q4 2025.

• Other Operating Expenses for Q4 2025 came in at $56.7 million, up 648.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.7 million (up 648.12% YoY), and the FY2025 annual result was $56.7 million, up 648.12% from the prior year.
• Other Operating Expenses climbed to $56.7 million in Q4 2025 per RNAC's latest filing, from $7.6 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $56.7 million in Q4 2025 and troughed at $710000.0 in Q4 2023.
• A 3-year average of $21.7 million and a median of $7.6 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses soared 967.46% in 2024, then surged 648.12% in 2025.
• A 3-year view of Other Operating Expenses shows it stood at $710000.0 in 2023, then soared by 967.46% to $7.6 million in 2024, then surged by 648.12% to $56.7 million in 2025.
• Business Quant data shows RNAC's Other Operating Expenses at $56.7 million in Q4 2025, $7.6 million in Q4 2024, and $710000.0 in Q4 2023.